Versuchen GOLD - Frei
DAM Capital bets on earnings stability
Mint Chennai
|January 12, 2026
India’s only listed pure-play investment bank, DAM Capital Advisors Ltd, plans to deploy its capital reserves into recurring, fee-based businesses to reduce the inherent volatility of investment banking, managing director and chief executive Dharmesh Mehta told Mint.
The firm will use cash reserves to build fee-based businesses: MD and CEO Dharmesh Mehta
While merchant banking remains the firm’s primary earnings driver, DAM Capital is evaluating asset-light ancillary services that require minimal capital deployment and limited balance-sheet risk to diversify its revenue base.
The Mumbai-based investment bank reported a cash balance of ₹287 crore as of the first half of the 2025-26 fiscal year. “A portion of this is required as working capital for the institutional equities business, but a part of it is also dry powder for potential ventures into businesses like alternative investment funds (AIFs), retail broking, and wealth management,” Mehta said.
“We will look at everything that generates fees without large cash burn or high balance-sheet risk. Wealth management today is a valuation-driven segment, not profits. For a new entrant, it requires significant upfront investment. We will build these businesses when we get the right team or the right platform at reasonable valuations.”
Diese Geschichte stammt aus der January 12, 2026-Ausgabe von Mint Chennai.
Abonnieren Sie Magzter GOLD, um auf Tausende kuratierter Premium-Geschichten und über 9.000 Zeitschriften und Zeitungen zuzugreifen.
Sie sind bereits Abonnent? Anmelden
WEITERE GESCHICHTEN VON Mint Chennai
Mint Chennai
Lenskart wants artificial intelligence to test your eyes
It expects AI-enabled eye testing to become the default foundational layer of eyecare delivery
3 mins
January 13, 2026
Mint Chennai
More companies to take a hit as labour codes debut
Reworked gratuity and leave encashments spell additional expenses for India Inc
2 mins
January 13, 2026
Mint Chennai
HC lifts ban on Zydus cancer biosimilar till patent expiry
In a relief for Zydus Lifesciences, a division bench of the Delhi High Court on Monday allowed the drugmaker to sell and market its biosimilar of the anticancer drug nivolumab in India, citing public interest.
2 mins
January 13, 2026
Mint Chennai
Trump’s investigation of Powell is also a warning to the next Fed chair
The criminal investigation into Federal Reserve Chair Jerome Powell isn’t ultimately about the Fed’s headquarters, or Powell, or even interest rates.
3 mins
January 13, 2026
Mint Chennai
States flag Almont-Kid syrup as tests find contaminants
Syrup found ‘Not of Standard Quality’ with contaminants like toxic ethylene glycol
1 mins
January 13, 2026
Mint Chennai
India at 100: Our choices today will define the next two decades
India's 2047 ambition is not guaranteed but achievable if we address all the potential pitfalls along our development path
4 mins
January 13, 2026
Mint Chennai
Now, inheritance works without probate—but why it still matters
Heirs can now act on a valid will without court cases, easing delays and unlocking assets in undisputed cases
6 mins
January 13, 2026
Mint Chennai
Why VCs have a new deep-tech playbook
where fundraising starts to drag,\" said Chand.
1 min
January 13, 2026
Mint Chennai
TCS, HCLTech deliver Q3 revenue surprise
clearer.
2 mins
January 13, 2026
Mint Chennai
US productivity is rising and it risks warping monetary policy
America's neutral rate ought to be going up but will the Fed listen?
3 mins
January 13, 2026
Listen
Translate
Change font size
